Authors:
Zsuzsanna Suba Országos Onkológiai Intézet Sebészeti és Molekuláris Tumorpatológiai Osztály Budapest Ráth György u. 7–9. 1122

Search for other papers by Zsuzsanna Suba in
Current site
Google Scholar
PubMed
Close
and
Miklós Kásler Országos Onkológiai Intézet Fej- Nyak, Állcsont- és Rekonstrukciós Sebészet, Onkológiai Helyreállító Plasztikai Sebészet és Lézersebészeti Osztály Budapest

Search for other papers by Miklós Kásler in
Current site
Google Scholar
PubMed
Close
Restricted access

A szexuális szteroidhormonok és a metabolikus folyamatok szoros kölcsönhatása jól ismert. Az inzulin szabályozza a humán szexuál- és szteroidhormon-képzést, és módosítja a hormonok szignáljait receptorszinten is. Az inzulinrezisztencia és a kompenzatórikus túlzott inzulintermelés androgéntúlsúllyal és ösztrogénhiánnyal társul. Ezek a hormonális változások cardiovascularis betegségekre és malignus tumorokra hajlamosítanak. Egészséges nőknél az ösztrogéntúlsúly az androgénnel szemben igen előnyös, mivel védelmet biztosít az inzulinrezisztencia és annak szövődményei ellen. Menopauza után viszont egyre gyakoribb az inzulinrezisztencia, ami a nemi hormonok egyensúlyzavarával, az ösztrogénhiánnyal és az androgéntúlsúllyal társul. Ez magyarázza, hogy az idős nők hajlamosabbak rákmegelőző állapotokra és malignus daganatokra, összehasonlítva az ugyanolyan korú férfiakkal. A női nemi hormonok (ösztrogén, ösztradiol) jótékony hatással vannak az energiaforgalomra, a cukor-, a zsír- és a fehérje-anyagcserére, továbbá a zsírszövet-lerakódás szabályozásában is jelentős szerepet játszanak. Akár mérsékelt, akár súlyos a szérumban az ösztrogénkoncentráció csökkenése, mindenképpen hajlamosít inzulinrezisztenciára. Fiatal nőkben az elhúzódó vagy szabálytalan menstruációs ciklusok és a fertilitás zavarai rendszerint inzulinrezisztenciával vagy 2-es típusú diabetesszel társulnak. Menopauza után az ösztrogénszint jelentős csökkenése növeli a testsúlyt és elsősorban a centrális, hasi régióban okoz zsírlerakódást. Ezzel párhuzamosan a glükóztolerancia is romlik, ami metabolikus szindrómát, illetve 2-es típusú diabetest eredményez. Az ösztrogénhiányos férfi nagyon ritka, ilyenkor súlyos 2-es típusú diabetes lép fel szövődményként. Mivel az inzulinrezisztencia és az ösztrogénhiány együttesen jelentős rákrizikófaktornak tekinthető, számos lehetőségünk van a veszélyeztetett betegeknél a malignus tumorok megelőzésére. Daganatos betegek esetében a hormonális zavarok felderítése és kezelése hatékony adjuváns terápiának ígérkezik. Orv. Hetil., 2012, 153, 125–136.

  • Kahn, C. R., Folli, F.: Molecular determinant of insulin action. Hormon Res., 1993, 39, 93–101.

    Folli F. , 'Molecular determinant of insulin action ' (1993 ) 39 Hormon Res. : 93 -101 .

    • Search Google Scholar
  • Reaven, G. M.: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes, 1988, 37, 1595–1607.

    Reaven G. M. , 'Banting lecture 1988: Role of insulin resistance in human disease ' (1988 ) 37 Diabetes : 1595 -1607 .

    • Search Google Scholar
  • Suba, Zs.: Insulin resistance, hyperinsulinemia and cancer risk, Chapter 2. In: Estrogen versus Cancer. Nova Science Publishers Inc, New York, 2009, pp. 19–40.

    Suba Zs. , '', in Estrogen versus Cancer , (2009 ) -.

  • Björnström, L., Sjöberg, M.: Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol., 2005, 19, 833–842.

    Sjöberg M. , 'Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes ' (2005 ) 19 Mol. Endocrinol. : 833 -842 .

    • Search Google Scholar
  • Reckelhoff, J. F.: Sex steroids, cardiovascular disease, and hypertension. Hypertension, 2005, 45, 170–174.

    Reckelhoff J. F. , 'Sex steroids, cardiovascular disease, and hypertension ' (2005 ) 45 Hypertension : 170 -174 .

    • Search Google Scholar
  • Suba, Zs.: Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis. Pathol. Oncol. Res., 2011, oct. 9. [Epub ahead of print]

  • Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 1999, 22, 141–146.

    Rosenfield R. L. , 'Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome ' (1999 ) 22 Diabetes Care : 141 -146 .

    • Search Google Scholar
  • Faustini-Fustini, M., Rochira, V., Carani, C.: Oestrogen deficiency in men: where are we today? Eur. J. Endocrinol., 1999, 140, 111–129.

    Carani C. , 'Oestrogen deficiency in men: where are we today? ' (1999 ) 140 Eur. J. Endocrinol. : 111 -129 .

    • Search Google Scholar
  • Schneider, J. G., Tompkins, C., Blumenthal, R. S., et al.: The metabolic syndrome in women. Cardiol. Rev., 2006, 14, 286–291.

    Blumenthal R. S. , 'The metabolic syndrome in women ' (2006 ) 14 Cardiol. Rev. : 286 -291 .

    • Search Google Scholar
  • Wu, S. I., Chou, P., Tsai, S. T.: The impact of years since menopause on the development of impaired glucose tolerance. J. Clin. Epidemiol., 2001, 54, 117–120.

    Tsai S. T. , 'The impact of years since menopause on the development of impaired glucose tolerance ' (2001 ) 54 J. Clin. Epidemiol. : 117 -120 .

    • Search Google Scholar
  • Nestler, J. E., Jakubowicz, D. J., de Vargas, A. F., et al.: Insulin stimulates testosterone biosynthesis by human thecal cells from women polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab., 1998, 83, 2001–2005.

    Vargas A. F. , 'Insulin stimulates testosterone biosynthesis by human thecal cells from women polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system ' (1998 ) 83 J. Clin. Endocrinol. Metab. : 2001 -2005 .

    • Search Google Scholar
  • DeFronzo, R. A., Ferrannini, E.: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14, 173–194.

    Ferrannini E. , 'Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease ' (1991 ) 14 Diabetes Care : 173 -194 .

    • Search Google Scholar
  • Bloomgarden, Z. T.: Second world congress on the insulin resistance syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care, 2005, 28, 1821–1830.

    Bloomgarden Z. T. , 'Second world congress on the insulin resistance syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy ' (2005 ) 28 Diabetes Care : 1821 -1830 .

    • Search Google Scholar
  • Wrighting Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 2002, 288, 321–333.

    'Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial ' (2002 ) 288 JAMA : 321 -333 .

    • Search Google Scholar
  • Suba, Z.: Gender-related hormonal risk factors for oral cancer. Pathol. Oncol. Res., 2007, 13, 195–202.

    Suba Z. , 'Gender-related hormonal risk factors for oral cancer ' (2007 ) 13 Pathol. Oncol. Res. : 195 -202 .

    • Search Google Scholar
  • Suba, Z.: Common soil of smoking-associated and hormone-related cancers: estrogen deficiency. Oncol. Rev., 2010, 4, 73–87.

    Suba Z. , 'Common soil of smoking-associated and hormone-related cancers: estrogen deficiency ' (2010 ) 4 Oncol. Rev. : 73 -87 .

    • Search Google Scholar
  • Ragaz, J., Wilson, K., Frohlich, J., et al.: Dual estrogen effects on breast cancer: endogenous estrogen stimulates, exogenous estrogen protects. Further investigation of estrogen chemoprevention is warranted. Cancer Res., 2010, 70 (suppl 24), 441.

    Frohlich J. , 'Dual estrogen effects on breast cancer: endogenous estrogen stimulates, exogenous estrogen protects. Further investigation of estrogen chemoprevention is warranted ' (2010 ) 70 Cancer Res. : 441 -.

    • Search Google Scholar
  • Gupta, K., Krishnaswamy, G., Karnad, A., et al.: Insulin: A novel factor in carcinogenesis. Am. J. Med. Sci., 2002, 323, 140–145.

    Karnad A. , 'Insulin: A novel factor in carcinogenesis ' (2002 ) 323 Am. J. Med. Sci. : 140 -145 .

    • Search Google Scholar
  • Yu, H., Rohan, T.: Role of insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst., 2000, 92, 1472–1489.

    Rohan T. , 'Role of insulin-like growth factor family in cancer development and progression ' (2000 ) 92 J. Natl. Cancer Inst. : 1472 -1489 .

    • Search Google Scholar
  • Muti, P., Quattrin, T., Grant, B. J., et al.: Fasting glucose is a risk factor for breast cancer. Cancer Epidemiol. Biomark. & Prev., 2002, 11, 1361–1368.

    Grant B. J. , 'Fasting glucose is a risk factor for breast cancer ' (2002 ) 11 Cancer Epidemiol. Biomark. & Prev. : 1361 -1368 .

    • Search Google Scholar
  • Balkau, B., Kahn, H.: Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: The Paris Prospective Study. Diabetes Care, 2001, 24, 843–849.

    Kahn H. , 'Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: The Paris Prospective Study ' (2001 ) 24 Diabetes Care : 843 -849 .

    • Search Google Scholar
  • McKeown-Eyssen, G.: Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol.; Biomark. Prev., 1994, 3, 687–695.

    McKeown-Eyssen G. , 'Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? ' (1994 ) 3 Cancer Epidemiol.; Biomark. Prev. : 687 -695 .

    • Search Google Scholar
  • Yeung, N. G., Husain, I., Waterfall, N.: Diabetes mellitus and bladder cancer. An epidemiological relationship? Pathol. Oncol. Res., 2003, 9, 30–31.

    Waterfall N. , 'Diabetes mellitus and bladder cancer. An epidemiological relationship? ' (2003 ) 9 Pathol. Oncol. Res. : 30 -31 .

    • Search Google Scholar
  • Barnard, R. J., Aronson, W. J., Tymchuk, C. N., et al.: Prostate cancer: another aspect of the insulin-resistance syndrome? Obes. Rev., 2002, 3, 303–308.

    Tymchuk C. N. , 'Prostate cancer: another aspect of the insulin-resistance syndrome? ' (2002 ) 3 Obes. Rev. : 303 -308 .

    • Search Google Scholar
  • Ujpál, M., Matos, O., Bibók, Gy., et al.: Diabetes and oral tumors in Hungary. Epidemiological correlations. Diabetes Care, 2004, 27, 770–774.

    Bibók Gy. , 'Diabetes and oral tumors in Hungary. Epidemiological correlations ' (2004 ) 27 Diabetes Care : 770 -774 .

    • Search Google Scholar
  • Suba, Z., Barabás, J., Szabó, Gy., et al.: Increased prevalence of diabetes and obesity in patients with salivary gland tumors. Diabetes Care, 2005, 28, 228.

    Szabó Gy. , 'Increased prevalence of diabetes and obesity in patients with salivary gland tumors ' (2005 ) 28 Diabetes Care : 228 -.

    • Search Google Scholar
  • Key, T. J., Applyby, P. N., Reeves, G. K.: Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst., 2003, 95, 1218–1226.

    Reeves G. K. , 'Body mass index, serum sex hormones and breast cancer risk in postmenopausal women ' (2003 ) 95 J. Natl. Cancer Inst. : 1218 -1226 .

    • Search Google Scholar
  • Soliman, P. T., Oh, J. C., Schmeler, K. M., et al.: Risk factors for young premenopausal women with endometrial cancer. Obstet. Gynecol., 2005, 105, 575–580.

    Schmeler K. M. , 'Risk factors for young premenopausal women with endometrial cancer ' (2005 ) 105 Obstet. Gynecol. : 575 -580 .

    • Search Google Scholar
  • Cowey, S., Hardy, R. W.: The metabolic syndrome: A high-risk state for cancer? Am. J. Pathol., 2006, 169, 1505–1522.

    Hardy R. W. , 'The metabolic syndrome: A high-risk state for cancer? ' (2006 ) 169 Am. J. Pathol. : 1505 -1522 .

    • Search Google Scholar
  • Beatson, T. G.: On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new treatment with illustrative cases. Lancet, 1896, 2, 104–107.

    Beatson T. G. , 'On the treatment of inoperable cases of carcinoma of the mamma. Suggestion for a new treatment with illustrative cases ' (1896 ) 2 Lancet : 104 -107 .

    • Search Google Scholar
  • Berrino, F., Muti, P., Micheli, A., et al.: Serum sex hormone levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst., 1996, 88, 291–296.

    Micheli A. , 'Serum sex hormone levels after menopause and subsequent breast cancer ' (1996 ) 88 J. Natl. Cancer Inst. : 291 -296 .

    • Search Google Scholar
  • La Vecchia, C., Brinton, L. A., McTiernan, A.: Menopause, hormone replacement therapy and cancer. Maturitas, 2001, 39, 97–115.

    McTiernan A. , 'Menopause, hormone replacement therapy and cancer ' (2001 ) 39 Maturitas : 97 -115 .

    • Search Google Scholar
  • Feigelson, H. S., Henderson, B. E.: Estrogens and breast cancer. Carcinogenesis, 1996, 17, 2279–2284.

    Henderson B. E. , 'Estrogens and breast cancer ' (1996 ) 17 Carcinogenesis : 2279 -2284 .

    • Search Google Scholar
  • Colditz, G. A., Hankinson, S. E., Hunter, D. J., et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med., 1995, 332, 1589–1593.

    Hunter D. J. , 'The use of estrogens and progestins and the risk of breast cancer in postmenopausal women ' (1995 ) 332 N. Engl. J. Med. : 1589 -1593 .

    • Search Google Scholar
  • Diamanti-Kandarakis, E.: Hormone replacement therapy and risk of malignancy. Curr. Opinion Obstet. Gynecol., 2004, 16, 73–78.

    Diamanti-Kandarakis E. , 'Hormone replacement therapy and risk of malignancy ' (2004 ) 16 Curr. Opinion Obstet. Gynecol. : 73 -78 .

    • Search Google Scholar
  • Key, T. J., Pike, M. C.: The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br. J. Cancer, 1988, 57, 205–212.

    Pike M. C. , 'The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk ' (1988 ) 57 Br. J. Cancer : 205 -212 .

    • Search Google Scholar
  • Toniolo, P. G., Levitz, M., Zeleniuch-Jacquotte, A., et al.: A prospective study of endogenous estrogens and breast cancer in post-menopausal women. J. Natl. Cancer Inst., 1995, 86, 1076–1082.

    Zeleniuch-Jacquotte A. , 'A prospective study of endogenous estrogens and breast cancer in post-menopausal women ' (1995 ) 86 J. Natl. Cancer Inst. : 1076 -1082 .

    • Search Google Scholar
  • Henderson, B. E., Ross, R. K., Pike, M. C.: Hormonal chemoprevention of cancer in women. Science, 1993, 259, 633–638.

    Pike M. C. , 'Hormonal chemoprevention of cancer in women ' (1993 ) 259 Science : 633 -638 .

    • Search Google Scholar
  • Hulka, B. S., Liu, E. T., Lininger, R. A.: Steroid hormones and risk of breast cancer. Cancer, 1993, 74, 1111–1124.

    Lininger R. A. , 'Steroid hormones and risk of breast cancer ' (1993 ) 74 Cancer : 1111 -1124 .

    • Search Google Scholar
  • Pike, M., Bernstein, L., Spicer, D.: Exogenous hormones and breast cancer risk. In: Neiderhuber, J. (ed.). Current Therapy in Oncology. BC Decker, St. Louis, MO, 1993, 292–302.

    Spicer D. , '', in Current Therapy in Oncology , (1993 ) -.

  • Liehr, J. G.: Is estradiol a genotoxic and mutagenic carcinogen? Endocr. Rev., 2000, 21, 40–54.

    Liehr J. G. , 'Is estradiol a genotoxic and mutagenic carcinogen? ' (2000 ) 21 Endocr. Rev. : 40 -54 .

    • Search Google Scholar
  • Greenwald, P., Caputo, T. A., Wolfgang, P. E.: Endometrial cancer after menopausal use of estrogens. Obstet. Gynecol., 1977, 50, 239–243.

    Wolfgang P. E. , 'Endometrial cancer after menopausal use of estrogens ' (1977 ) 50 Obstet. Gynecol. : 239 -243 .

    • Search Google Scholar
  • Rodriguez, C., Patel, A. V., Calle, E. E., et al.: Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA, 2001, 285, 1460–1465.

    Calle E. E. , 'Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women ' (2001 ) 285 JAMA : 1460 -1465 .

    • Search Google Scholar
  • Negri, E., Tzonou, A., Beral, V., et al.: Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int. J. Cancer, 1999, 80, 848–85l.

    Beral V. , 'Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies ' (1999 ) 80 Int. J. Cancer : 848 -85l .

    • Search Google Scholar
  • Lacey, J. V., Mink, P. J., Lubin, J. H., et al.: Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA, 2002, 288, 334–341.

    Lubin J. H. , 'Menopausal hormone replacement therapy and risk of ovarian cancer ' (2002 ) 288 JAMA : 334 -341 .

    • Search Google Scholar
  • International Agency for Research on Cancer: Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and postmenopausal hormone therapy. Vol. 72. IARC, Lyon, France, 1999.

    '', in Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception and postmenopausal hormone therapy. Vol. 72 , (1999 ) -.

  • Russo, J., Fernandez, S. V., Russo, P. A., et al.: 17-beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J., 2006, 20, 1622–1634.

    Russo P. A. , '17-beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells ' (2006 ) 20 FASEB J. : 1622 -1634 .

    • Search Google Scholar
  • Dickson, R. B., Gelmann, E. P., Knabbe, C., et al.: Mechanisms of estrogenic and antiestrogenic regulation of growth of human breast carcinoma. In: Klijn, J. G. M. (ed.). Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. Raven Press, New York, 1987, 381–403.

    Knabbe C. , '', in Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents , (1987 ) -.

  • Katzenellenbogen, B. S.: Estrogen receptors: bioactivity and interactions with cell signaling pathways. Biol. Reprod., 1996, 54, 287–293.

    Katzenellenbogen B. S. , 'Estrogen receptors: bioactivity and interactions with cell signaling pathways ' (1996 ) 54 Biol. Reprod. : 287 -293 .

    • Search Google Scholar
  • Ames, B. N., Shigenaga, M. K., Gold, L. S.: DNA lesions, inducible DNA repair and cell division: three key factors in mutagenesis and carcinogenesis. Environ. Perspect., 1993, 101, 35–44.

    Gold L. S. , 'DNA lesions, inducible DNA repair and cell division: three key factors in mutagenesis and carcinogenesis ' (1993 ) 101 Environ. Perspect. : 35 -44 .

    • Search Google Scholar
  • Li, J. J., Li, S. A.: Estrogen carcinogenesis in hamster tissues: a critical review. Endocr. Rev., 1990, 11, 524–531.

    Li S. A. , 'Estrogen carcinogenesis in hamster tissues: a critical review ' (1990 ) 11 Endocr. Rev. : 524 -531 .

    • Search Google Scholar
  • Nandi, S.: Role of hormones in mammary neoplasia. Cancer Res., 1978, 38, 4046–4049.

    Nandi S. , 'Role of hormones in mammary neoplasia ' (1978 ) 38 Cancer Res. : 4046 -4049 .

    • Search Google Scholar
  • Clark, R. B., Howell, A., Potten, C. S., et al.: Dissociation between steroid receptor expression and cell proliferation in human breast. Cancer Res., 1997, 57, 4987–4991.

    Potten C. S. , 'Dissociation between steroid receptor expression and cell proliferation in human breast ' (1997 ) 57 Cancer Res. : 4987 -4991 .

    • Search Google Scholar
  • Ashburn, S. P., Han, X., Liehr, J. G.: Microsomal hydroxylation of 2- and 4-fluorestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis. Mol. Pharmacol., 1993, 43, 534–541.

    Liehr J. G. , 'Microsomal hydroxylation of 2- and 4-fluorestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis ' (1993 ) 43 Mol. Pharmacol. : 534 -541 .

    • Search Google Scholar
  • Ursin, G., London, S., Stanczyk, F. Z., et al.: Urinary 2-hydroxyestrone/16 alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J. Natl. Cancer. Inst., 1999, 91, 1067–1072.

    Stanczyk F. Z. , 'Urinary 2-hydroxyestrone/16 alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women ' (1999 ) 91 J. Natl. Cancer. Inst. : 1067 -1072 .

    • Search Google Scholar
  • Salama, S. A., Kamel, M., Awad, M., et al.: Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase. Int. J. Cancer, 2008, 123, 1246–1254.

    Awad M. , 'Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase ' (2008 ) 123 Int. J. Cancer : 1246 -1254 .

    • Search Google Scholar
  • Tsutsui, T., Barrett, J. C.: Neoplastic transformation of cultured mammalian cells by estrogens and estrogen-like chemicals. Environ. Health Perspect., 1997, 105 (Suppl. 3), 619–624.

    Barrett J. C. , 'Neoplastic transformation of cultured mammalian cells by estrogens and estrogen-like chemicals ' (1997 ) 105 Environ. Health Perspect. : 619 -624 .

    • Search Google Scholar
  • Banerjee, S. K., Banerjee, S., Li, S. A., et al.: Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens. Mutat. Res., 1994, 311, 191–197.

    Li S. A. , 'Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens ' (1994 ) 311 Mutat. Res. : 191 -197 .

    • Search Google Scholar
  • Barrett, J. C., Wong, A., McLachlan, J. A.: Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science, 1981, 212, 1402–1404.

    McLachlan J. A. , 'Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci ' (1981 ) 212 Science : 1402 -1404 .

    • Search Google Scholar
  • Mobley, J. A., Bhat, A. S., Brueggemeier, R. W.: Measurement of oxidative DNA damage by catechol estrogens and analogues in vitro. Chem. Res. Toxicol., 1999, 12, 270–277.

    Brueggemeier R. W. , 'Measurement of oxidative DNA damage by catechol estrogens and analogues in vitro ' (1999 ) 12 Chem. Res. Toxicol. : 270 -277 .

    • Search Google Scholar
  • Michos, C., Kiortsis, D. N., Evangelou, A., et al.: Antioxidant protection during menstrual cycle: the effects of estradiol on ascorbic-dehydroascorbic acid plasma levels and total antioxidant plasma status in eumenorrhoic women during menstrual cycle. Acta Obstet. Gynecol. Scand., 2006, 85, 960–965.

    Evangelou A. , 'Antioxidant protection during menstrual cycle: the effects of estradiol on ascorbic-dehydroascorbic acid plasma levels and total antioxidant plasma status in eumenorrhoic women during menstrual cycle ' (2006 ) 85 Acta Obstet. Gynecol. Scand. : 960 -965 .

    • Search Google Scholar
  • Freedman, N. D., Lacey, J. V., Hollenbeck, A. R., et al.: The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP Cohort. Cancer, 2010, 116, 1572–1581.

    Hollenbeck A. R. , 'The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP Cohort ' (2010 ) 116 Cancer : 1572 -1581 .

    • Search Google Scholar
  • McGrath, M., Michaud, D. S., De Vivo, I.: Hormonal and reproductive factors and the risk of bladder cancer in women. Am. J. Epidemiol., 2006, 163, 236–244.

    Vivo I. , 'Hormonal and reproductive factors and the risk of bladder cancer in women ' (2006 ) 163 Am. J. Epidemiol. : 236 -244 .

    • Search Google Scholar
  • La Vecchia, C., D’Avanzo, B., Franceschi, S., et al.: Menstrual and reproductive factors and gastric-cancer in women. Int. J. Cancer, 1994, 59, 761–764.

    Franceschi S. , 'Menstrual and reproductive factors and gastric-cancer in women ' (1994 ) 59 Int. J. Cancer : 761 -764 .

    • Search Google Scholar
  • Britt, K., Ashworth, A., Smalley, M.: Pregnancy and the risk of breast cancer. Endocr. Relat. Cancer, 2007, 14, 907–933.

    Smalley M. , 'Pregnancy and the risk of breast cancer ' (2007 ) 14 Endocr. Relat. Cancer : 907 -933 .

    • Search Google Scholar
  • Wolpert, B. J., Amr, S., Ezzat, S., et al.: Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas, 2010, 67, 353–357.

    Ezzat S. , 'Estrogen exposure and bladder cancer risk in Egyptian women ' (2010 ) 67 Maturitas : 353 -357 .

    • Search Google Scholar
  • Teras, L. R., Patel, A. V., Rodriguez, C., et al.: Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women. Cancer Causes Control, 2005, 16, 1035–1040.

    Rodriguez C. , 'Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women ' (2005 ) 16 Cancer Causes Control : 1035 -1040 .

    • Search Google Scholar
  • Bosetti, C., Negri, E., Franceschi, S., et al.: Risk factors for oral and pharyngeal cancer in women: a study from Italy and Switzerland. Br. J. Cancer, 2000, 82, 204–207.

    Franceschi S. , 'Risk factors for oral and pharyngeal cancer in women: a study from Italy and Switzerland ' (2000 ) 82 Br. J. Cancer : 204 -207 .

    • Search Google Scholar
  • Suba, Zs.: Estrogen deficiency as cancer risk factor. Chapter 5, In: Estrogen versus Cancer. Nova Science Publishers Inc, New York, 2009, pp. 85–106.

    Suba Zs. , '', in Estrogen versus Cancer , (2009 ) -.

  • Olsson, H., Bladström, A. M., Ingvar, C.: Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet. Gynecol., 2003, 102, 565–570.

    Ingvar C. , 'Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? ' (2003 ) 102 Obstet. Gynecol. : 565 -570 .

    • Search Google Scholar
  • Gallus, S., Bosetti, C., Franceschi, S., et al.: Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br. J. Cancer, 2001, 85, 341–345.

    Franceschi S. , 'Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors ' (2001 ) 85 Br. J. Cancer : 341 -345 .

    • Search Google Scholar
  • Parazzini, F., La Vecchia, C., Negri, E., et al.: Case-control study of estrogen replacement therapy and risk of cervical cancer. Br. Med. J., 1997, 315, 85–88.

    Negri E. , 'Case-control study of estrogen replacement therapy and risk of cervical cancer ' (1997 ) 315 Br. Med. J. : 85 -88 .

    • Search Google Scholar
  • Fernandez, E., Gallus, S., Bosetti, C., et al.: Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int. J. Cancer, 2003, 105, 408–412.

    Bosetti C. , 'Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies ' (2003 ) 105 Int. J. Cancer : 408 -412 .

    • Search Google Scholar
  • Kreuzer, M., Gerken, M., Heinrich, J., et al.: Hormonal factors and risk of lung cancer among women? Int. J. Epidemiol., 2003, 32, 263–271.

    Heinrich J. , 'Hormonal factors and risk of lung cancer among women? ' (2003 ) 32 Int. J. Epidemiol. : 263 -271 .

    • Search Google Scholar
  • Anderson, G. L., Judd, H. L., Kaunitz, A. M., et al. for the Women’s Health Initiative Investigators: Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: The Women’s Health Initiative randomized trial. JAMA, 2003, 290, 1739–1748.

    Kaunitz A. M. , 'Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: The Women’s Health Initiative randomized trial ' (2003 ) 290 JAMA : 1739 -1748 .

    • Search Google Scholar
  • Schapiro, S.: False alarm: postmenopausal hormone therapy and ovarian cancer. Climacteric, 2007, 10, 466–470.

    Schapiro S. , 'False alarm: postmenopausal hormone therapy and ovarian cancer ' (2007 ) 10 Climacteric : 466 -470 .

    • Search Google Scholar
  • Anderson, G. L., Limacher, M., Assaf, A. R., et al. for the Women’s Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA, 2004, 291, 1701–1712.

    Assaf A. R. , 'Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial ' (2004 ) 291 JAMA : 1701 -1712 .

    • Search Google Scholar
  • LaCroix, A. Z., Chlebowski, R. T., Manson, J. E., et al.: Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. A randomized controlled trial. JAMA, 2011, 305, 1305–1314.

    Manson J. E. , 'Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. A randomized controlled trial ' (2011 ) 305 JAMA : 1305 -1314 .

    • Search Google Scholar
  • Nilsson, S., Makela, S., Treuter, E., et al.: Mechanisms of estrogen action. Physiol. Rev., 2001, 81, 1535–1565.

    Treuter E. , 'Mechanisms of estrogen action ' (2001 ) 81 Physiol. Rev. : 1535 -1565 .

  • Hall, J. M., McDonnell, D. P.: The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinol., 1999, 140, 5566–5578.

    McDonnell D. P. , 'The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens ' (1999 ) 140 Endocrinol. : 5566 -5578 .

    • Search Google Scholar
  • Segars, J., Driggers, P.: Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes. Trends. Endocrin. Metab., 2002, 13, 349–354.

    Driggers P. , 'Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes ' (2002 ) 13 Trends. Endocrin. Metab. : 349 -354 .

    • Search Google Scholar
  • Helguero, L. A., Faulds, M. H., Gustafsson, J. A., et al.: Estrogen receptors α (ERα) and β (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene, 2005, 24, 6605–6616.

    Gustafsson J. A. , 'Estrogen receptors α (ERα) and β (ERβ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11 ' (2005 ) 24 Oncogene : 6605 -6616 .

    • Search Google Scholar
  • Suba, Zs.: Antiestrogen or estrogen as anticancer drug, Chapter 4. In: Hoffmann, A. B. (ed.). Sex Hormones, Development, Regulation and Disorders. Nova Science Publishers Inc., New York, 2011.

    Suba Zs. , '', in Sex Hormones, Development, Regulation and Disorders , (2011 ) -.

  • Razandi, M., Pedram, A., Greene, G. L., et al.: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol. Endocrinol., 1999, 13, 307–319.

    Greene G. L. , 'Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells ' (1999 ) 13 Mol. Endocrinol. : 307 -319 .

    • Search Google Scholar
  • Driggers, P. H., Segars, J. H.: Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrin. Metab., 2002, 13, 422–427.

    Segars J. H. , 'Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling ' (2002 ) 13 Trends Endocrin. Metab. : 422 -427 .

    • Search Google Scholar
  • Kato, S., Endoh, H., Masuhiro, Y., et al.: Activation of the estrogen receptor though phosphorylation by mitogen-activated protein kinase. Science, 1995, 270, 1491–1494.

    Masuhiro Y. , 'Activation of the estrogen receptor though phosphorylation by mitogen-activated protein kinase ' (1995 ) 270 Science : 1491 -1494 .

    • Search Google Scholar
  • Lundholt, B. K., Briand, P., Lykkesfeldt, A. E.: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res. Treat., 2001, 67, 199–214.

    Lykkesfeldt A. E. , 'Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways ' (2001 ) 67 Breast Cancer Res. Treat. : 199 -214 .

    • Search Google Scholar
  • Kásler, M., Polgár, C., Fodor, J.: Current status of treatment for early-stage invasive breast cancer. [A korai stádiumú emlőrákok kezelésének jelenlegi helyzete.]. Orv. Hetil., 2009, 150, 1013–1021. [Hungarian]

    Fodor J. , 'Current status of treatment for early-stage invasive breast cancer. [A korai stádiumú emlőrákok kezelésének jelenlegi helyzete.] ' (2009 ) 150 Orv. Hetil. : 1013 -1021 .

    • Search Google Scholar
  • Massarweh, S., Schiff, R.: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor crosstalk. Endocr. Relat. Cancer, 2006, 13 (Suppl. 1), S15–S24.

    Schiff R. , 'Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor crosstalk ' (2006 ) 13 Endocr. Relat. Cancer : S15 -S24 .

    • Search Google Scholar
  • Marquez-Garban, D. C., Chen, H. W., Fishbein, M. C., et al.: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids, 2007, 72, 135–143.

    Fishbein M. C. , 'Estrogen receptor signaling pathways in human non-small cell lung cancer ' (2007 ) 72 Steroids : 135 -143 .

    • Search Google Scholar
  • Nelson, K. G., Takahashi, T., Bossert, N. L., et al.: Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation. Proceed. Natl. Acad. Sci. USA, 1991, 88, 21–25.

    Bossert N. L. , 'Epidermal growth factor replaces estrogen in the stimulation of female genital-tract growth and differentiation ' (1991 ) 88 Proceed. Natl. Acad. Sci. USA : 21 -25 .

    • Search Google Scholar
  • Curtis, S. W., Washburn, T., Sewall, C., et al.: Physiological coupling of growth factor and steroid receptor signaling pathway: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proceed. Natl. Acad. Sci. USA, 1996, 93, 12626–12630.

    Sewall C. , 'Physiological coupling of growth factor and steroid receptor signaling pathway: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor ' (1996 ) 93 Proceed. Natl. Acad. Sci. USA : 12626 -12630 .

    • Search Google Scholar
  • Barros, R. P. A., Machado, U. F., Gustafsson, J. A.: Estrogen receptors: new players in diabetes mellitus. Trends Mol. Med., 2006, 12, 425–431.

    Gustafsson J. A. , 'Estrogen receptors: new players in diabetes mellitus ' (2006 ) 12 Trends Mol. Med. : 425 -431 .

    • Search Google Scholar
  • Choi, S. B., Jang, J. S., Park, S.: Estrogen and exercise may enhance β-cell function and mass via insulin receptor substrate 2 induction in ovarectomized diabetic rats. Endocrinology, 2005, 146, 4786–4794.

    Park S. , 'Estrogen and exercise may enhance β-cell function and mass via insulin receptor substrate 2 induction in ovarectomized diabetic rats ' (2005 ) 146 Endocrinology : 4786 -4794 .

    • Search Google Scholar
  • Bryzgalova, G., Gao, H., Ahren, B., et al.: Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia, 2006, 49, 588–597.

    Ahren B. , 'Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver ' (2006 ) 49 Diabetologia : 588 -597 .

    • Search Google Scholar
  • Welch, R. D., Gorski, J.: Regulation of glucose transporters by estradiol in the immature rat uterus. Endocrinology, 1999, 140, 3602–3608.

    Gorski J. , 'Regulation of glucose transporters by estradiol in the immature rat uterus ' (1999 ) 140 Endocrinology : 3602 -3608 .

    • Search Google Scholar
  • Godsland, I. F., Walton, C., Stevenson, J. C.: Impact of menopause on metabolism. In: Diamond, M. P., Naftolin, K. (eds.). Metabolism in the female life cycle. Ares Seerono Symposia, Rome, 1993, 171–189.

    Stevenson J. C. , '', in Metabolism in the female life cycle , (1993 ) -.

  • Jones, M. E., Thorburn, A. W., Britt, K. L., et al.: Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc. Natl. Acad. Sci. USA, 2000, 97, 12735–12740.

    Britt K. L. , 'Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity ' (2000 ) 97 Proc. Natl. Acad. Sci. USA : 12735 -12740 .

    • Search Google Scholar
  • Muraki, K., Okuya, S., Tanizawa, Y.: Estrogen receptor alpha regulates insulin sensitivity trough IRS-1 thyrosin phosphorylation in mature 3T3-L1 adipocytes. Endocr. J., 2006, 53, 841–851.

    Tanizawa Y. , 'Estrogen receptor alpha regulates insulin sensitivity trough IRS-1 thyrosin phosphorylation in mature 3T3-L1 adipocytes ' (2006 ) 53 Endocr. J. : 841 -851 .

    • Search Google Scholar
  • Shi, J., Simpkins, J. W.: 17β-estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am. J. Physiol., 1997, 272, 1016–1022.

    Simpkins J. W. , '17β-estradiol modulation of glucose transporter 1 expression in blood-brain barrier ' (1997 ) 272 Am. J. Physiol. : 1016 -1022 .

    • Search Google Scholar
  • Rosenbaum, D., Haber, R. S., Dunaif, A.: Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am. J. Physiol., 1993, 264, 197–202.

    Dunaif A. , 'Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes ' (1993 ) 264 Am. J. Physiol. : 197 -202 .

    • Search Google Scholar
  • Nagira, K., Sasaoka, T., Wada, T., et al.: Altered subcellular distribution of estrogen receptor is implicated in estradiol-induced dual regulation of insulin signaling in 3T3-L1 adipocytes. Endocrinology, 2006, 147, 1020–1028.

    Wada T. , 'Altered subcellular distribution of estrogen receptor is implicated in estradiol-induced dual regulation of insulin signaling in 3T3-L1 adipocytes ' (2006 ) 147 Endocrinology : 1020 -1028 .

    • Search Google Scholar
  • Leung, K. C., Johannson, G., Leung, G. M., et al.: Estrogen regulation of growth hormone action. Endocrine Rev., 2004, 25, 693–721.

    Leung G. M. , 'Estrogen regulation of growth hormone action ' (2004 ) 25 Endocrine Rev. : 693 -721 .

    • Search Google Scholar
  • Walsh, B. W., Schiff, I., Rosner, B., et al.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl. J. Med., 1991, 325, 1196–1204.

    Rosner B. , 'Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins ' (1991 ) 325 New Engl. J. Med. : 1196 -1204 .

    • Search Google Scholar
  • Hamden, K., Carreau, S., Ellouz, F., et al.: Protective effect of 17beta-estradiol on oxidative stress and liver dysfunction in aged male rats. J. Physiol. Biochem., 2007, 63, 195–201.

    Ellouz F. , 'Protective effect of 17beta-estradiol on oxidative stress and liver dysfunction in aged male rats ' (2007 ) 63 J. Physiol. Biochem. : 195 -201 .

    • Search Google Scholar
  • Croston, G. E., Milan, L. B., Marschke, K. B., et al.: Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology, 1997, 138, 3779–3786.

    Marschke K. B. , 'Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes ' (1997 ) 138 Endocrinology : 3779 -3786 .

    • Search Google Scholar
  • Pallottini, V., Bulzomi, P., Galluzzo, P., et al.: Estrogen regulation of adipose tissue functions: Involvement of estrogen receptor isoforms. Infect. Disord. Drug Targets, 2008, 8, 52–60.

    Galluzzo P. , 'Estrogen regulation of adipose tissue functions: Involvement of estrogen receptor isoforms ' (2008 ) 8 Infect. Disord. Drug Targets : 52 -60 .

    • Search Google Scholar
  • Macotela, Y., Boucher, J., Tran, T. T., et al.: Sex and depot differences in adipocyte insulin sensitivity and glucose. Diabetes, 2009, 58, 803–812.

    Tran T. T. , 'Sex and depot differences in adipocyte insulin sensitivity and glucose ' (2009 ) 58 Diabetes : 803 -812 .

    • Search Google Scholar
  • Poehlman, E. T., Toth, M. J., Gardner, A. W.: Changes in energy balance and body composition at menopause. Ann. Intern. Med., 1995, 123, 673–675.

    Gardner A. W. , 'Changes in energy balance and body composition at menopause ' (1995 ) 123 Ann. Intern. Med. : 673 -675 .

    • Search Google Scholar
  • Suba, Z.: Correlations between obesity and risk for salivary gland tumors. Cancer Res. J., 2009, 3, 55–68.

    Suba Z. , 'Correlations between obesity and risk for salivary gland tumors ' (2009 ) 3 Cancer Res. J. : 55 -68 .

    • Search Google Scholar
  • Calle, E. E., Kaaks, R.: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4, 579–591.

    Kaaks R. , 'Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms ' (2004 ) 4 Nat. Rev. Cancer : 579 -591 .

    • Search Google Scholar
  • Baghaei, F., Rosmond, R., Westberg, L., et al.: The CYP19 gene and association with androgens and abdominal obesity in premenopausal women. Obesity Res., 2003, 11, 578–585.

    Westberg L. , 'The CYP19 gene and association with androgens and abdominal obesity in premenopausal women ' (2003 ) 11 Obesity Res. : 578 -585 .

    • Search Google Scholar
  • Björntorp, P.: The regulation of adipose tissue distribution in humans. Int. J. Obes. Relat. Metab. Disord., 1996, 20, 291–302.

    Björntorp P. , 'The regulation of adipose tissue distribution in humans ' (1996 ) 20 Int. J. Obes. Relat. Metab. Disord. : 291 -302 .

    • Search Google Scholar
  • Sartor, B. M., Dickey, R. P.: Polycystic ovarian syndrome and the metabolic syndrome. Am. J. Med., 2005, 330, 336–342.

    Dickey R. P. , 'Polycystic ovarian syndrome and the metabolic syndrome ' (2005 ) 330 Am. J. Med. : 336 -342 .

    • Search Google Scholar
  • Cara, J. F., Rosenfield, R. L.: Insulin-like growth factor I and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal-interstitial cells. Endrocrinology, 1988, 123, 733–739.

    Rosenfield R. L. , 'Insulin-like growth factor I and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal-interstitial cells ' (1988 ) 123 Endrocrinology : 733 -739 .

    • Search Google Scholar
  • Attia, G. R., Rainey, W. E., Carr, B. R.: Metformin directly inhibits androgen production in human thecal cells. Fertil. Steril., 2001, 76, 517–524.

    Carr B. R. , 'Metformin directly inhibits androgen production in human thecal cells ' (2001 ) 76 Fertil. Steril. : 517 -524 .

    • Search Google Scholar
  • Moghetti, P., Castello, R., Negri, C., et al.: Insulin infusion amplifies 17-(alpha)-hydroxy-corticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J. Clin. Endocrinol. Metab., 1996, 81, 881–886.

    Negri C. , 'Insulin infusion amplifies 17-(alpha)-hydroxy-corticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity ' (1996 ) 81 J. Clin. Endocrinol. Metab. : 881 -886 .

    • Search Google Scholar
  • Christakou, C., Diamanti-Kandarakis, E.: Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Women’s Health, 2008, 4, 583–594.

    Diamanti-Kandarakis E. , 'Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome ' (2008 ) 4 Women’s Health : 583 -594 .

    • Search Google Scholar
  • Solomon, C. G., Hu, F. B., Dunaif, A., et al.: Long or highly irregular menstrual cycles as a marker for risk of type-2 diabetes mellitus. JAMA, 2001, 286, 2421–2426.

    Dunaif A. , 'Long or highly irregular menstrual cycles as a marker for risk of type-2 diabetes mellitus ' (2001 ) 286 JAMA : 2421 -2426 .

    • Search Google Scholar
  • Elting, M. W., Dorsen, T. J. M., Bezemer, P. D., et al.: Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum. Reprod., 2001, 16, 556–560.

    Bezemer P. D. , 'Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population ' (2001 ) 16 Hum. Reprod. : 556 -560 .

    • Search Google Scholar
  • Gadducci, A., Gargini, A., Palla, E., et al.: Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol. Endocrinol., 2005, 20, 200–208.

    Palla E. , 'Polycystic ovary syndrome and gynecological cancers: is there a link? ' (2005 ) 20 Gynecol. Endocrinol. : 200 -208 .

    • Search Google Scholar
  • Pierpoint, T., McKeigue, P. M., Isaacs, A. J., et al.: Mortality of women with polycystic ovary syndrome at long-term follow-up. J. Clin. Epidemiol., 1998, 51, 581–586.

    Isaacs A. J. , 'Mortality of women with polycystic ovary syndrome at long-term follow-up ' (1998 ) 51 J. Clin. Epidemiol. : 581 -586 .

    • Search Google Scholar
  • King, H., Rewers, M., WHO Ad Hoc Diabetes Reporting Group: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care, 1993, 16, 157–177.

    Rewers M. , 'Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults ' (1993 ) 16 Diabetes Care : 157 -177 .

    • Search Google Scholar
  • Wilson, P. W. E.: Does estrogen reduce glycemic levels? Diabetes Care, 1998, 21, 1585–1586.

    Wilson P. W. E. , 'Does estrogen reduce glycemic levels? ' (1998 ) 21 Diabetes Care : 1585 -1586 .

    • Search Google Scholar
  • Proudler, A. J., Felton, C. V., Stevenson, J. C.: Aging and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin. Sci., 1992, 83, 489–494.

    Stevenson J. C. , 'Aging and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women ' (1992 ) 83 Clin. Sci. : 489 -494 .

    • Search Google Scholar
  • Gohlke-Barwolf, C.: Coronary artery disease: is menopause a risk factor? Basic. Res. Cardiol., 2000, 95, 177–183.

    Gohlke-Barwolf C. , 'Coronary artery disease: is menopause a risk factor? ' (2000 ) 95 Basic. Res. Cardiol. : 177 -183 .

    • Search Google Scholar
  • Hirose, K., Toyama, T., Iwata, H., et al.: Insulin, insulin-like growth factor-1 and breast cancer risk in Japanese women. Asian Pac. J. Cancer Prev., 2003, 4, 239–246.

    Iwata H. , 'Insulin, insulin-like growth factor-1 and breast cancer risk in Japanese women ' (2003 ) 4 Asian Pac. J. Cancer Prev. : 239 -246 .

    • Search Google Scholar
  • Goodwin, P. J., Boyd, N. F., Hanna, W., et al.: Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. Nutr. Cancer, 1997, 27, 284–292.

    Hanna W. , 'Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk ' (1997 ) 27 Nutr. Cancer : 284 -292 .

    • Search Google Scholar
  • Godsland, I. F.: Oestrogens and insulin secretion. Diabetologia, 2005, 48, 2213–2220.

    Godsland I. F. , 'Oestrogens and insulin secretion ' (2005 ) 48 Diabetologia : 2213 -2220 .

    • Search Google Scholar
  • Rapp, K., Schroeder, J., Klenk, J., et al.: Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia, 2006, 49, 945–952.

    Klenk J. , 'Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria ' (2006 ) 49 Diabetologia : 945 -952 .

    • Search Google Scholar
  • Morimoto, L. M., White, E., Chen, Z., et al.: Obesity, body size and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control, 2002, 13, 741–751.

    Chen Z. , 'Obesity, body size and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States) ' (2002 ) 13 Cancer Causes Control : 741 -751 .

    • Search Google Scholar
  • McCullough, M. L., Patel, A. V., Patel, R., et al.: Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 73–79.

    Patel R. , 'Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype ' (2008 ) 17 Cancer Epidemiol. Biomarkers Prev. : 73 -79 .

    • Search Google Scholar
  • Takács, D., Koppány, F., Mihályi, S., et al.: Decreased oral cancer risk by moderate alcohol consumption in non-smoker postmenopausal women. Oral Oncol., 2011, 47, 537–540.

    Mihályi S. , 'Decreased oral cancer risk by moderate alcohol consumption in non-smoker postmenopausal women ' (2011 ) 47 Oral Oncol. : 537 -540 .

    • Search Google Scholar
  • Kásler, M., Ottó, S.: European and Hungarian national tasks in oncology. [Európai és magyar feladatok az onkológia területén.]. Magy. Onkol., 2008, 52, 21–33. [Hungarian]

    Ottó S. , 'European and Hungarian national tasks in oncology. [Európai és magyar feladatok az onkológia területén.] ' (2008 ) 52 Magy. Onkol. : 21 -33 .

    • Search Google Scholar
  • Collapse
  • Expand
The author instructions are available in PDF.
Instructions for Authors in Hungarian  HERE
Mendeley citation style is available  HERE.

 

Főszerkesztő - Editor-in-Chief:
 
Zoltán PAPP (professor emeritus, Semmelweis Egyetem, Szülészeti és Nőgyógyászati Klinika, Budapest)

Read the professional career of Zoltán PAPP HERE.

All scientific publications of Zoltán PAPP are collected in the Hungarian Scientific Bibliography.

Főszerkesztő-helyettesek - Assistant Editors-in-Chief: 

  • Erzsébet FEHÉR (professor emeritus, Semmelweis Egyetem, Anatómiai, Szövet- és Fejlődéstani Intézet)
  • Krisztina HAGYMÁSI (egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)

Főmunkatársak - Senior Editorial Specialists:

  • László KISS (a Debreceni Egyetem habilitált doktora)
  • Gabriella LENGYEL (ny. egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)
  • Alajos PÁR (professor emeritus, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)

 A Szerkesztőbizottság tagjai – Members of the Editorial Board:

  • Péter ANDRÉKA (főigazgató, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • Géza ÁCS Jr. (egyetemi tanár Floridában)
  • Csaba BALÁZS (egyetemi tanár, Budai Endokrinközpont, Budapest)
  • Zoltán BENYÓ (egyetemi tanár, Semmelweis Egyetem, Transzlációs Medicina Intézet, Budapest)
  • Dániel BERECZKI (egyetemi tanár, Semmelweis Egyetem, Neurológiai Klinika, Budapest)
  • Anna BLÁZOVICS (professor emeritus, Semmelweis Egyetem, Farmakognóziai Intézet, Budapest)
  • Lajos BOGÁR (egyetemi tanár, Pécsi Tudományegyetem, Klinikai Központ, Aneszteziológiai és Intenzív Terápiás Intézet, Pécs)
  • Katalin DARVAS (professor emeritus, Semmelweis Egyetem, Általános Orvostudományi Kar, Sebészeti, Transzplantációs és Gasztroenterológiai Klinika, továbbá Aneszteziológiai és Intenzív Terápiás Klinika, Budapest)
  • Elek DINYA (professor emeritus, biostatisztikus, Semmelweis Egyetem, Budapest)
  • Attila DOBOZY (professor emeritus, Szegedi Tudományegyetem, Bőrgyógyászati Klinika, Szeged)
  • Levente EMŐDY (professor emeritus, Pécsi Tudományegyetem, Általános Orvostudományi Kar, Mikrobióligiai Intézet, Pécs)
  • András FALUS (professor emeritus, Semmelweis Egyetem, Genetikai, Sejt- és Immunbiológiai Intézet, Budapest)
  • Béla FÜLESDI (egyetemi tanár, Debreceni Egyetem, Aneszteziológiai és Intenzív Terápiás Klinika, Debrecen)
  • István GERA (professor emeritus, Semmelweis Egyetem, Fogorvostudományi Kar, Parodontológiai Klinika, Budapest)
  • Beáta GASZTONYI (egyetemi magántanár, kórházi főorvos, Zala Megyei Kórház, Belgyógyászat, Zalaegerszeg)
  • Béla GÖMÖR (professor emeritus, Budai Irgalmasrendi Kórház, Reumatológiai Osztály, Budapest)
  • János HANKISS (professor emeritus, Markusovszky Lajos Oktató Kórház, Belgyógyászati Osztály, Szombathely)
  • Katalin HEGEDŰS (habilitált egyetemi docens, Semmelweis Egyetem, Általános Orvosi Kar, Magatartástudományi Intézet, Budapest)
  • Andor HIRSCHBERG (c. egyetemi tanár, Észak-budai Szent János Centrumkórház, Fül-, Orr-, Gége-, Fej-Nyak és Szájsebészeti Osztály, Budapest)
  • Örs Péter HORVÁTH (professor emeritus, Pécsi Tudományegyetem, Sebészeti Klinika, Pécs)
  • Béla HUNYADY (egyetemi tanár, Somogy Megyei Kaposi Mór Kórház, Belgyógyászat, Kaposvár)
  • Péter IGAZ (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • Ferenc JAKAB (c. egyetemi tanár, Uzsoki Utcai Kórház, Sebészet, Budapest)
  • Zoltán JANKA (professor emeritus, Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar és Klinikai Központ, Pszichiátriai Klinika, Szeged)
  • András JÁNOSI (c. egyetemi tanár, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
  • György JERMENDY (egyetemi tanár, Bajcsy-Zsilinszky Kórház, Belgyógyászat, Budapest)
  • László KALABAY (egyetemi tanár, Semmelweis Egyetem, Családorvosi Tanszék, Budapest)
  • Anita KAMONDI (egyetemi tanár, Országos Mentális, Ideggyógyászati és Idegsebészeti Intézet, Neurológiai Osztály, Budapest)
  • János KAPPELMAYER (egyetemi tanár, Debreceni Egyetem, Laboratóriumi Medicina Intézet, Debrecen)
  • Éva KELLER (ny. egyetemi tanár, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • András KISS (egyetemi tanár, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
  • Lajos KULLMANN (ny. egyetemi tanár, Országos Rehabilitációs Intézet, Budapest)
  • Emese MEZŐSI (egyetemi tanár, Pécsi Tudományegyetem, I. Belgyógyászati Klinika, Pécs)
  • László MÓDIS (egyetemi tanár, Debreceni Egyetem, Általános Orvostudományi Kar, Szemészeti Tanszék, Debrecen)
  • Györgyi MŰZES (egyetemi docens, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Bálint NAGY (egyetemi tanár, Debreceni Egyetem, Humángenetikai Tanszék, Debrecen)
  • Endre NAGY (egyetemi tanár, Debreceni Egyetem, Belgyógyászati Intézet, Debrecen) 
  • Péter NAGY (egyetemi tanár, Semmelweis Egyetem, I. Patológiai és Kísérleti Rákkutató Intézet, Budapest)
  • Viktor NAGY (főorvos, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Zoltán Zsolt NAGY (egyetemi tanár, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • György PARAGH (professor emeritus, Debreceni Egyetem, Általános Orvostudományi Kar, Belgyógyászati Intézet, Debrecen)
  • Attila PATÓCS (tudományos főmunkatárs, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Edit PAULIK (intézetvezető egyetemi tanár, Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar, Népegészségtani Intézet, Szeged)
  • Gabriella PÁR (egyetemi docens, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)
  • György PFLIEGLER (egyetemi tanár, Debreceni Egyetem, Ritka Betegségek Tanszéke, Debrecen)
  • István RÁCZ (egyetemi tanár, főorvos, Petz Aladár Megyei Oktató Kórház, Belgyógyászat, Győr)
  • Bernadette ROJKOVICH (osztályvezető főorvos, Betegápoló Irgalmasrend Budai Irgalmasrendi Kórház, Budapest)
  • Imre ROMICS (professor emeritus, Semmelweis Egyetem, Urológiai Klinika, Budapest)
  • László Jr. ROMICS (Angliában dolgozik)
  • Ferenc ROZGONYI (professor emeritus, Semmelweis Egyetem, Laboratóriumi Medicina Intézet, Budapest)
  • Imre RURIK (egyetemi tanár, Debreceni Egyetem, Családorvosi és Foglalkozás-egészségügyi Tanszék, Debrecen)
  • Péter SCHMIDT (házi gyermekorvos, Győr)
  • Gábor SIMONYI (vezető főorvos, Szent Imre Kórház, Anyagcsere Központ, Budapest)
  • Gábor Márk SOMFAI (egyetemi docens, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • Anikó SOMOGYI (ny. egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Péter SÓTONYI (professor emeritus, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
  • Péter Jr. SÓTONYI (egyetemi tanár, Semmelweis Egyetem, Városmajori Szív- és Érsebészeti Klinika, Budapest)
  • Ildikó SÜVEGES (professor emeritus, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
  • György SZABÓ (professor emeritus, Semmelweis Egyetem, Arc-Állcsont-Szájsebészeti és Fogászati Klinika, Budapest)
  • György SZEIFERT (egyetemi magántanár, Semmelweis Egyetem, Általános Orvostudományi Kar, Idegsebészeti Tanszék, Budapest)
  • Miklós SZENDRŐI (professor emeritus, Semmelweis Egyetem, Ortopédiai Klinika, Budapest)
  • Miklós TÓTH (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
  • László TRINGER (professor emeritus, Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika, Budapest)
  • Tivadar TULASSAY (professor emeritus, Semmelweis Egyetem, I. Gyermekgyógyászati Klinika, Budapest)
  • Zsolt TULASSAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
  • Lívia VASAS (ny. könyvtárigazgató, Semmelweis Egyetem, Központi Könyvtár, Budapest)
  • Barna VÁSÁRHELYI (egyetemi tanár, Semmelweis Egyetem, Laboratóriumi Medicina Intézet, Budapest)
  • László VÉCSEI (professor emeritus, Szegedi Tudományegyetem, Neurológiai Klinika, Szeged)
  • Gábor WINKLER (egyetemi tanár, Szent János Kórház, Belgyógyászati Osztály, Budapest)

Nemzetközi szerkesztőbizottság - International Editorial Board:

  • Elnök/President Péter SÓTONYI (Budapest)
  • Ernest ADEGHATE (Al Ain)
  • Ferenc ANTONI (Edinburgh)
  • Maciej BANACH (Łódź)
  • Klára BERENCSI (Rosemont)
  • Angelo BIGNAMINI (Milano)
  • Anupam BISHAYEE (Signal Hill)
  • Hubert E. BLUM (Freiburg)
  • G. László BOROS (Los Angeles)
  • Frank A. CHERVENAK (New York)
  • József DÉZSY (Wien)
  • Peter ECKL (Salzburg)
  • Péter FERENCI (Wien)
  • Madelaine HAHN (Erlangen)
  • S. Tamás ILLÉS (Bruxelles)
  • Michael KIDD (Toronto)
  • Andrzej KOKOSZKA (Warsaw)
  • Márta KORBONITS (London)
  • Asim KURJAK (Zagreb)
  • Manfred MAIER (Wien)
  • Lajos OKOLICSÁNYI (Padova)
  • Amado Salvador PENA (Amsterdam)
  • Guliano RAMADORI (Goettingen)
  • Olivér RÁCZ (Košice)
  • Roberto ROMERO (Detroit)
  • Rainer SCHÖFL (Linz)
  • Zvi VERED (Tel Aviv)
  • Josef VESELY (Olomouc)
  • Ákos ZAHÁR (Hamburg)

Akadémiai Kiadó Zrt. 1117 Budapest
Budafoki út 187-189.
A épület, III. emelet
Phone: (+36 1) 464 8235
Email: orvosihetilap@akademiai.hu

  • Web of Science SCIE
  • Scopus
  • Medline
  • CABELLS Journalytics

2022  
Web of Science  
Total Cites
WoS
1295
Journal Impact Factor 0.6
Rank by Impact Factor

Medicine, General & Integral (Q4)

Impact Factor
without
Journal Self Cites
0.3
5 Year
Impact Factor
0.5
Journal Citation Indicator 0.15
Rank by Journal Citation Indicator

Medicine, General & Integral (Q3)

Scimago  
Scimago
H-index
24
Scimago
Journal Rank
0.182
Scimago Quartile Score

Medicine (miscellaneous) (Q4)

Scopus  
Scopus
Cite Score
1.0
Scopus
CIte Score Rank
General Medicine 530/830 (36th PCTL)
Scopus
SNIP
0.290

2021  
Web of Science  
Total Cites
WoS
1386
Journal Impact Factor 0,707
Rank by Impact Factor Medicine, General & Internal 158/172
Impact Factor
without
Journal Self Cites
0,407
5 Year
Impact Factor
0,572
Journal Citation Indicator 0,15
Rank by Journal Citation Indicator Medicine, General & Internal 214/329
Scimago  
Scimago
H-index
23
Scimago
Journal Rank
0,184
Scimago Quartile Score Medicine (miscellaneous) (Q4)
Scopus  
Scopus
Cite Score
0,9
Scopus
CIte Score Rank
General Medicine 528/826 (Q3)
Scopus
SNIP
0,242

2020  
Total Cites 1277
WoS
Journal
Impact Factor
0,540
Rank by Medicine, General & Internal 155/169 (Q4)
Impact Factor  
Impact Factor 0,310
without
Journal Self Cites
5 Year 0,461
Impact Factor
Journal  0,17
Citation Indicator  
Rank by Journal  Medicine, General & Internal 203/313 (Q4)
Citation Indicator   
Citable 261
Items
Total 229
Articles
Total 32
Reviews
Scimago 21
H-index
Scimago 0,176
Journal Rank
Scimago Medicine (miscellaneous) Q4
Quartile Score  
Scopus 921/1187=0,8
Scite Score  
Scopus General Medicine 494/793 (Q3)
Scite Score Rank  
Scopus 0,283
SNIP  
Days from  28
submission  
to acceptance  
Days from  114
acceptance  
to publication  
Acceptance 72%
Rate

2019  
Total Cites
WoS
1 085
Impact Factor 0,497
Impact Factor
without
Journal Self Cites
0,212
5 Year
Impact Factor
0,396
Immediacy
Index
0,126
Citable
Items
247
Total
Articles
176
Total
Reviews
71
Cited
Half-Life
6,1
Citing
Half-Life
7,3
Eigenfactor
Score
0,00071
Article Influence
Score
0,045
% Articles
in
Citable Items
71,26
Normalized
Eigenfactor
0,08759
Average
IF
Percentile
10,606
Scimago
H-index
20
Scimago
Journal Rank
0,176
Scopus
Scite Score
864/1178=0,4
Scopus
Scite Score Rank
General Medicine 267/529 (Q3)
Scopus
SNIP
0,254
Acceptance
Rate
73%

 

Orvosi Hetilap
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Printed Color Illustrations 20 EUR (or 5000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2023 Online subsscription: 858 EUR / 1157 USD
Print + online subscription: 975 EUR / 1352 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Orvosi Hetilap
Language Hungarian
Size A4
Year of
Foundation
1857
Volumes
per Year
1
Issues
per Year
52
Founder Markusovszky Lajos Alapítvány -- Lajos Markusovszky Foundation
Founder's
Address
H-1088 Budapest, Szentkriályi u. 46.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0030-6002 (Print)
ISSN 1788-6120 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Dec 2023 140 1 0
Jan 2024 128 3 0
Feb 2024 51 0 0
Mar 2024 24 1 0
Apr 2024 62 0 0
May 2024 101 0 0
Jun 2024 19 0 0